Eledon Pharmaceuticals, Inc.
NASDAQ:ELDNBiotechnology
+$0.11 today
- Market cap
- $171.45M
- Beta
- 0.97
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.70
Volume 1.12M
Average 1.37M
ELDN Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Eledon Pharmaceuticals, Inc.NASDAQ: ELDN
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $2.2M fell 23.1% year over year, ahead of the -31.5% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 10.7% from the prior quarter. Over 3 fiscal years it compounded at +8.6% a year.
Context
- Stock-based compensation increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -23.1% holds above the trailing-twelve-month pace of -31.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 10.45M USD
- Year-over-year change
- -20.4%
- 4-year CAGR
- +7.2%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.45M | -20.4% |
| FY2024 | 2024-12-31 | 13.12M | +100.5% |
| FY2023 | 2023-12-31 | 6.55M | -19.7% |
| FY2022 | 2022-12-31 | 8.15M | +3.2% |
| FY2021 | 2021-12-31 | 7.9M | — |
Stock-Based Compensation vs competitors
How ELDN compares with its peers on the latest reported figures
- ELDN's LTM Mar 2026 stock-based compensation of $9.79M is the 6th largest of the 11 companies compared; the peer median is $9.78M.
- Its year-over-year change of -31.5% is the 8th highest of 11, against a peer median of -11.2%.
- Over three fiscal years its annual growth of +8.6% compares with a peer median of +0.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $33.74M | -35.1% | -23.4% | — | |
| LTM Mar 2026 | $19.27M | -0.0% | +25.6% | 335.8% | |
| LTM Mar 2026 | $17.5M | -62.1% | -23.7% | — | |
| LTM Mar 2026 | $13.6M | -8.6% | +16.5% | 37.3% | |
| LTM Mar 2026 | $10.44M | +45.6% | +16.4% | 517.7% | |
| LTM Mar 2026 | $9.79M | -31.5% | +8.6% | — | |
| LTM Mar 2026 | $9.12M | -45.7% | -30.1% | 23.6% | |
| LTM Mar 2026 | $9.07M | -23.3% | -16.5% | 4.2% | |
| LTM Mar 2026 | $8.33M | +7.1% | +52.3% | 57.3% | |
| LTM Mar 2026 | $6.81M | -13.7% | -16.3% | 3.0% | |
| LTM Mar 2026 | $5.84M | -6.8% | +38.9% | — | |
| Peer median (excluding ELDN) | $9.78M | -11.2% | +0.1% | 37.3% | |
Competitors are the stored peer set for ELDN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (34.51M) | (87.97M) | (116.54M) | (36.18M) | (45.62M) |
| Depreciation & Amortization | 195K | 373K | 374K | 359K | 313K |
| Deferred Income Tax | (2.35M) | 0 | 0 | 431K | 5K |
| Stock-Based Compensation | 7.9M | 8.15M | 6.55M | 13.12M | 10.45M |
| Change in Working Capital | (152K) | 2.37M | (4.92M) | 8.71M | 7.65M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.14M | 2.08M | (2.6M) | 7.75M | 6.72M |
| Other Working Capital | (2.3M) | 287K | (2.32M) | 959K | 928K |
| Other Non-Cash Items | 0 | 48.65M | 75.01M | (33.71M) | (35.15M) |
| Operating Cash Flow | (28.91M) | (28.42M) | (39.53M) | (47.27M) | (62.34M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (78.29M) | (156.13M) | (161.13M) |
| Sales of Investments | 0 | 0 | 33M | 85.82M | 171.93M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | (45.29M) | (70.31M) | 10.79M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | (449K) | 0 | 33.02M | 133.31M | 53.58M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 215K | 0 |
| Financing Cash Flow | (449K) | 0 | 33.02M | 133.52M | 53.81M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (29.36M) | (28.42M) | (51.8M) | 15.94M | 2.26M |
| Free Cash Flow | (28.91M) | (28.42M) | (39.53M) | (47.27M) | (62.34M) |
Eledon Pharmaceuticals, Inc.
NASDAQ:ELDN
Intrinsic Alpha fair value
Locked
Current Price
$2.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.